Jesse G. Dixon

International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI

Amy S. Ruppert, Jesse G. Dixon, Gilles Salles et al. · Blood · 2020 · 357 citations · Full text

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Carla Casulo, Jesse G. Dixon, Jennifer Le‐Rademacher et al. · Blood · 2022 · 154 citations · Full text

CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design

Kurt A. Jaeckle, Karla V. Ballman, Martin J. van den Bent et al. · Neuro-Oncology · 2020 · 108 citations · Full text

Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient–Level Analysis of Multiple Randomized Trials (SEAL)

Qian Shi, Norbert Schmitz, Fang‐Shu Ou et al. · Journal of Clinical Oncology · 2018 · 97 citations · Full text

Stereotactic Radiosurgery With or Without Whole-Brain Radiation Therapy for Limited Brain Metastases: A Secondary Analysis of the North Central Cancer Treatment Group N0574 (Alliance) Randomized Controlled Trial

Thomas M. Churilla, Karla V. Ballman, Paul D. Brown et al. · International Journal of Radiation Oncology*Biology*Physics · 2017 · 83 citations

Adaptive Radiotherapy, Neuro-oncology, Limited Brain Metastases +9